FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of cancer and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with privately-held Intermedica of Nizhny Novgorod, Russia for the distribution of the Sonablate 500 High Intensity Focused Ultrasound (“HIFU”) System. The agreement provides Intermedica with the rights to sell in Russia, Belarussia, Kazakstan and the Ukraine, and includes minimum purchase requirements.
